Advanced Malignant Solid Tumor

Oncology
5
Pipeline Programs
3
Companies
5
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
5
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Virogin Biotech
Virogin BiotechBC - Richmond
3 programs
3
Recombinant Human IL12/15 Dual-Regulated Oncolytic HSV-1 InjectionPhase 11 trial
Recombinant Human IL12/15 Dual-Regulated Oncolytic HSV-1 InjectionPhase 11 trial
Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 InjectionPhase 11 trial
Active Trials
NCT07262164Not Yet RecruitingEst. Aug 2028
NCT05477849RecruitingEst. Dec 2025
NCT04758897UnknownEst. Dec 2022
Molecular Partners
Molecular PartnersSchlieren-Zurich, Switzerland
1 program
1
MP0317, a tri-specific fibroblast activation proteinPhase 11 trial
Active Trials
NCT05098405Terminated46Est. Jan 2024
CT
1 program
1
TQB3303Phase 11 trial
Active Trials
NCT04275050UnknownEst. Apr 2022

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
Virogin BiotechRecombinant Human IL12/15 Dual-Regulated Oncolytic HSV-1 Injection
Virogin BiotechRecombinant Human IL12/15 Dual-Regulated Oncolytic HSV-1 Injection
Molecular PartnersMP0317, a tri-specific fibroblast activation protein
Virogin BiotechRecombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection
Chia Tai TianQing Pharmaceutical GroupTQB3303

Clinical Trials (5)

Total enrollment: 46 patients across 5 trials

NCT07262164Virogin BiotechRecombinant Human IL12/15 Dual-Regulated Oncolytic HSV-1 Injection

A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Biologic Effect of VG2062 in Patients With Solid Tumors

Start: Jan 2026Est. completion: Aug 2028
Phase 1Not Yet Recruiting
NCT05477849Virogin BiotechRecombinant Human IL12/15 Dual-Regulated Oncolytic HSV-1 Injection

A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Biologic Effect of VG2025 in Patients with Solid Tumors

Start: Aug 2022Est. completion: Dec 2025
Phase 1Recruiting
NCT05098405Molecular PartnersMP0317, a tri-specific fibroblast activation protein

First-in-human Safety and Tolerability of MP0317 in Patients With Relapsed/Refractory Advanced Solid Tumors

Start: Oct 2021Est. completion: Jan 202446 patients
Phase 1Terminated
NCT04758897Virogin BiotechRecombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection

Clinical Study of VG161 in Subjects With Advanced Malignant Solid Tumors

Start: Apr 2021Est. completion: Dec 2022
Phase 1Unknown
NCT04275050Chia Tai TianQing Pharmaceutical GroupTQB3303

A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3303 Tablets

Start: Apr 2020Est. completion: Apr 2022
Phase 1Unknown

Related Jobs in Oncology

Senior Research Associate, Immuno-Oncology

SystImmune
1m ago
$60K - $85K/yr

Research Associate I/II, Immuno-Oncology

SystImmune
1m ago

Office Administrator

SystImmune
1m ago
$60K - $80K/yr

Scientist/Sr Scientist

TwoStep Therapeutics
San Carlos
11m ago

Working Student Office Management Support (m/f/d)

Mindpeak
Hamburg
15m ago

Senior Medical Project Manager (m/f/d)

Mindpeak
Hamburg
15m ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 46 patients
3 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)